Work

Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

Year: 2023

Type: erratum

Source: Nature Medicine

DOI: 10.1038/s41591-023-02301-y

Authors: Jeremy Pettus, Schafer C. Boeder, Mark P. Christiansen, Douglas S. Denham, Timothy S. Bailey, Halis K. Akturk, Leslie J. Klaff, Julio Rosenstock, Mickie H. M. Cheng, Bruce W. Bode, Edgar D. Bautista, Ren Xu, Hai Yan, Dung Thai, Satish K. Garg, Samuel Klein

Institutions: University of California San Diego, Diablo Clinical Research, Clinical Trials of Texas, AMCR Institute, University of Colorado Anschutz, Rainier Clinical Research Center, Dallas Diabetes Research Center, Marin Endocrine Care and Research, Atlanta Diabetes Associates, Washington University in St. Louis, Sansum Diabetes Research Institute

Language: English

Topic: Diabetes Management and Research

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Health and Human Services, National Institutes of Health

Awards: Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes, G8663171237

OpenAlex ID: W4327811802

Cites:

Cited by: 1

Related to: 10